article thumbnail

The effectiveness of nanoparticles in chemotherapy

Drug Target Review

Hodge School of Pharmacy, recently received a five year, $2.49 The grant will enable her to investigate the interaction of nanoparticles with the immune system and cancer, supporting the development of new drug delivery systems. Macrophages were detected as the cells responsible for these negative effects.

article thumbnail

COVID-19 nasal vaccine candidate effective at preventing disease transmission

The Pharma Data

. “However, mucosal vaccination has been hampered by the shortage of efficient delivery of the antigen and therefore the need for appropriate adjuvants which will stimulate a strong immune reaction without toxicity.” A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

20/20 Offering Lab Test for Measuring Antibody Levels Associated with Vaccine Efficacy

The Pharma Data

The presence of serum antibodies against an infectious agent may be an indicator of immunity against said agent. These fingerstick collection kits will be especially useful at pharmacies administering vaccines that do not employ phlebotomists. 20/20’s Chief Scientific Officer.

Vaccine 52
article thumbnail

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

The Pharma Data

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., did not have antibodies at baseline: seronegative), as prior evidence suggested these patients were at greater risk. futility analysis). .

article thumbnail

Regeneron’s Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is First Combination Therapy to Receive FDA Emergency Use Authorization

The Pharma Data

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

article thumbnail

Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

The Pharma Data

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.

Virus 40
article thumbnail

Scaling Phage Therapy

Codon

Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. Phage therapies are sold at a pharmacy in Georgia.

Therapies 131